A lipoprotein(a) szerepe - Megvalaszolatlan kerdesek

Translated title of the contribution: The role of lipoprotein(a) - The 'game' is not over

Research output: Contribution to journalArticle

Abstract

The high plasma level of lipoprotein(a) [Lp(a)] is associated with higher morbidity and mortality of coronary heart disease. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. In contrast, the physiological function of the genetically highly determined Lp(a) is unknown. The metabolic fate of Lp(a) has also escaped our understanding. Due to numerous gaps in the knowledge about the Lp(a) therapeutic for influence of its plasma level is unresolved. There are few medications which have been shown to lower the plasma concentration of Lp(a), however since these drugs all have multiple other effects their use is not the choice of the therapy. A number of examinations suggest that elevated plasma low-density cholesterol (LDL) concentration is required for Lp(a) to contribute to atherosclerosis significantly. According to the results of intervention studies the best therapeutic option for high plasma Lp(a) level is to lower the plasma level of LDL.

Original languageHungarian
Pages (from-to)736-742
Number of pages7
JournalLege Artis Medicinae
Volume9
Issue number10
Publication statusPublished - 1999

Fingerprint

Lipoprotein(a)
Cholesterol
Coronary Disease
Atherosclerosis
Therapeutics
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A lipoprotein(a) szerepe - Megvalaszolatlan kerdesek. / Császár, A.

In: Lege Artis Medicinae, Vol. 9, No. 10, 1999, p. 736-742.

Research output: Contribution to journalArticle

@article{c45b0cbd8d674d6186096d042faa96d7,
title = "A lipoprotein(a) szerepe - Megvalaszolatlan kerdesek",
abstract = "The high plasma level of lipoprotein(a) [Lp(a)] is associated with higher morbidity and mortality of coronary heart disease. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. In contrast, the physiological function of the genetically highly determined Lp(a) is unknown. The metabolic fate of Lp(a) has also escaped our understanding. Due to numerous gaps in the knowledge about the Lp(a) therapeutic for influence of its plasma level is unresolved. There are few medications which have been shown to lower the plasma concentration of Lp(a), however since these drugs all have multiple other effects their use is not the choice of the therapy. A number of examinations suggest that elevated plasma low-density cholesterol (LDL) concentration is required for Lp(a) to contribute to atherosclerosis significantly. According to the results of intervention studies the best therapeutic option for high plasma Lp(a) level is to lower the plasma level of LDL.",
keywords = "Atherosclerosis, Blood coagulation, Cholesterol, Genetic factors, Lipoprotein(a), Therapy",
author = "A. Cs{\'a}sz{\'a}r",
year = "1999",
language = "Hungarian",
volume = "9",
pages = "736--742",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - A lipoprotein(a) szerepe - Megvalaszolatlan kerdesek

AU - Császár, A.

PY - 1999

Y1 - 1999

N2 - The high plasma level of lipoprotein(a) [Lp(a)] is associated with higher morbidity and mortality of coronary heart disease. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. In contrast, the physiological function of the genetically highly determined Lp(a) is unknown. The metabolic fate of Lp(a) has also escaped our understanding. Due to numerous gaps in the knowledge about the Lp(a) therapeutic for influence of its plasma level is unresolved. There are few medications which have been shown to lower the plasma concentration of Lp(a), however since these drugs all have multiple other effects their use is not the choice of the therapy. A number of examinations suggest that elevated plasma low-density cholesterol (LDL) concentration is required for Lp(a) to contribute to atherosclerosis significantly. According to the results of intervention studies the best therapeutic option for high plasma Lp(a) level is to lower the plasma level of LDL.

AB - The high plasma level of lipoprotein(a) [Lp(a)] is associated with higher morbidity and mortality of coronary heart disease. Its atherogenicity seems to be related to the similarity in structure with thrombohemostatic factors. In contrast, the physiological function of the genetically highly determined Lp(a) is unknown. The metabolic fate of Lp(a) has also escaped our understanding. Due to numerous gaps in the knowledge about the Lp(a) therapeutic for influence of its plasma level is unresolved. There are few medications which have been shown to lower the plasma concentration of Lp(a), however since these drugs all have multiple other effects their use is not the choice of the therapy. A number of examinations suggest that elevated plasma low-density cholesterol (LDL) concentration is required for Lp(a) to contribute to atherosclerosis significantly. According to the results of intervention studies the best therapeutic option for high plasma Lp(a) level is to lower the plasma level of LDL.

KW - Atherosclerosis

KW - Blood coagulation

KW - Cholesterol

KW - Genetic factors

KW - Lipoprotein(a)

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0033392564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033392564&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 736

EP - 742

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -